Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II study.
Fiche publication
Date publication
avril 2022
Journal
European journal of cancer (Oxford, England : 1990)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BORG Christophe, Dr VERNEREY Dewi, Dr KIM Stephano, Mme HENRIQUES Julie
Tous les auteurs :
Rousseau B, Boukerma AK, Henriques J, Cohen R, Lucidarme O, Borg C, Tournigand C, Kim S, Bachet JB, Mazard T, Louvet C, Chibaudel B, Vernerey D, Andre T, Hulin A
Lien Pubmed
Résumé
This prospective pharmacokinetic (PK) ancillary study of the TEXCAN phase II GERCOR trial of patients with chemorefractory metastatic colorectal cancer and treated with regorafenib (REGO) investigated correlations between overall survival (OS) and concentrations (C) of REGO and its active metabolites, M-2 and M-5.
Mots clés
Chemorefractory metastatic colorectal cancer, M-2, M-5, Pharmacokinetic, Pharmacological monitoring, Regorafenib, Survival
Référence
Eur J Cancer. 2022 Apr 27;168:99-107